NCCN Hematologic Malignancies Congress | Conference

Dr. Kumar on Properly Managing Patients With Multiple Myeloma

October 13th 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses properly managing patients with multiple myeloma.

Dr. Wierda Discusses the Role of Ibrutinib in CLL

October 11th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia.

Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

October 11th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Dr. Stone Discusses Monitoring MRD in AML

October 11th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.

Dr. Wong Discusses Monoclonal Antibodies in Plasma Cell Neoplasms

October 11th 2017

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses monoclonal antibodies in plasma cell neoplasms.

Mesa Highlights Guideline Updates in Myeloproliferative Neoplasms

October 11th 2017

The National Comprehensive Cancer Network guidelines for the management of polycythemia vera and essential thrombocythemia have been updated to create a more uniform system of management for healthcare providers to follow in clinical practice.

Dr. Callander on Treatment Considerations in Multiple Myeloma

October 10th 2017

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

Dr. Maloney on Challenges With CAR T-Cell Therapy in ALL

October 10th 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the challenges that exist in the use of CAR T-cell therapy in acute lymphocytic leukemia.

CAR T Cells Highly Successful in ALL

October 9th 2017

Defined composition CAR T cells directed against CD19 have potent anti-tumor activity in B cell malignancies, including acute lymphocytic leukemia.

New AML Drugs Approved and Under Investigation in 2017

October 9th 2017

After nearly 40 years with little in the way of drug development for the treatment of acute myeloid leukemia, four new drugs have been approved by the FDA in 2017 for AML, and several promising agents are in development.

Treatment for Relapsed/Refractory Multiple Myeloma Based on Biology, Time to Relapse

October 8th 2017

The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities.

Managing Newly-Diagnosed Multiple Myeloma

October 8th 2017

Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.

Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia

October 8th 2017

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Dr. Winter Discusses Response in Follicular Lymphoma

October 8th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.

New Therapies Being Developed Rapidly for Relapsed Hodgkin Lymphoma

October 8th 2017

In relapsed classical Hodgkin lymphoma, the era of therapies post-brentuximab vedotin is developing rapidly.

Wierda Discusses Novel Combinations, Sequencing in CLL

October 8th 2017

William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.

Data Emerges on Maintenance Therapies, Developing Treatments for Relapsed/Refractory FL

October 8th 2017

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

Dr. Kumar on the Management of Newly Diagnosed Patients With Multiple Myeloma

October 7th 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

Dr. Wierda Discusses Trials of Novel Combinations in CLL

October 7th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia.

Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML

October 8th 2016

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).